Table 2.
Sensitivity analysis and indirect-comparison meta-analysis results
| Urinary symptom score
|
Pain index score
|
General health index score
|
Sexual matters score
|
|||||
|---|---|---|---|---|---|---|---|---|
| I2 | MD (95% CI) | I2 | MD (95% CI) | I2 | MD (95% CI) | I2 | MD (95% CI) | |
| Sensitivity analysis | ||||||||
| High-quality study | 52% | −3.87 (−4.47, −3.28) | 0% | −2.71 (−3.00, −2.42) | 76% | −1.25 (−1.73, −0.77) | 75% | −0.36 (−0.64, −0.09) |
| Age ≤50 y | 36% | −3.77 (−4.27, −3.27) | 0% | −2.69 (−3.06, −2.32) | 0% | −1.05 (−1.24, −0.86) | 79% | −0.35 (−0.72, 0.01)* |
| >50 y | 94% | −5.35 (−11.01, 0.31)* | 0% | −1.85 (−2.18, −1.51) | 86% | −1.67 (−3.62, 0.28)* | 0% | −0.55 (−0.75, −0.34) |
| Stent <6F | 54% | −4.92 (−7.29, −2.54) | 0% | −2.74 (−3.03, −2.44) | 83% | −1.70 (−3.75, 0.34)* | 0% | −0.59 (−0.82, −0.37) |
| ≥6F | 95% | −4.15 (−5.79, −2.50) | 99% | −0.08 (−0.31, 0.15)* | 96% | −0.29 (−0.45, −0.14) | 75% | −0.33 (−0.65, −0.02) |
| Tamsulosin | 95% | −4.32 (−6.83, −1.82) | 99% | −0.52 (−0.78, −0.27) | 95% | −0.14 (−0.29, 0.01)* | 81% | −0.41 (−0.91, 0.09)* |
| Other α−blockers# | 58% | −3.94 (−4.98, −2.90) | 20% | −2.66 (−3.35, −1.97) | 89% | −1.48 (−2.62, −0.34) | 18% | −0.47 (−0.66, −0.29) |
| Indirect comparison | ||||||||
| Tamsulosin vs other α-blockers | −0.38 (−3.09, 2.33)* | 2.14 (1.41, 2.88) | 1.34 (0.19, 2.49) | 0.06 (−0.39, 0.51)* | ||||
Notes:
*
No significant difference was found.
#
Other α-blockers included alfuzosin and terazosin.
Abbreviations: y, years; MD, mean difference; CI, confidence interval.